Corlanor (ivabradine; Servier/Amgen/Ono Pharmaceutical) blocks f-channels and inhibits the f-current, a modulator of the heart's pacemaker activity. Heart rate (HR) depends on the speed of diastolic depolarization of myocytes from the sinus node. By binding to the f-channels of sinoatrial cells, Corlanor blocks the inward flow of sodium and potassium.
This prolongs the myocytes' depolarization phase, and slows HR. A lower HR decreases cardiac oxygen consumption, and prolonged diastolic times increase myocardial perfusion. Corlanor's improvements in overall oxygen levels help to reduce cardiovascular risk. The drug's pure HR-lowering properties prevent it from affecting contractility, or intracardiac conduction.
Key Topics Covered:
Corlanor: Chronic heart failure (CHF)
List of Figures
Figure 1: Corlanor for chronic heart failure - SWOT analysis
Figure 2: Drug assessment summary of Corlanor for chronic heart failure
Figure 3: Drug assessment summary of Corlanor for chronic heart failure
Figure 4: Corlanor sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
Table 1: Corlanor drug profile
Table 2: Corlanor pivotal phase III trial data in chronic heart failure
Table 3: Corlanor Phase II trial data in chronic heart failure
Table 4: Corlanor sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/jrc7wz/2018_corlanor?w=4